Bibliographic information
Recommendation
For people with chronic hepatitis B infection, serological testing for anti-HDV antibodies may be performed for all individuals who are HBsAg positive, as the preferred approach to scale up access to HDV diagnosis and linkage to care
Recommended in favor
Conditional
Certainty of evidence
Very low
Notes and Remarks
The 2024 recommendations focus on testing and case-finding for HDV infection. WHO recognizes that the HDV treatment landscape is rapidly evolving. Until recently, PEG-IFNα had been the only treatment option for CHD but had poor treatment outcomes, a significant sideeffect profile and many contraindications. WHO continues to monitor the outcomes of ongoing HDV treatment trials and will consider formal recommendations on treatment when further evidence becomes available.